RDIF, AstraZeneca and Unicorn Capital Partners invest in Target Medicals, developing aldosterone synthase inhibitor for the treatment of resistant arterial hypertension

This site uses cookies to make your browsing experience more convenient and personal. Cookies store useful information on your computer to help us improve the efficiency and relevance of our site for you. In some cases, they are essential to making the site work properly. By accessing this site, you consent to the use of cookies. Ok